In a phase I trial (ACE-Gastric-01), the novel ADC drug ARX788 exhibited good tolerability and antitumor activity in treating patients with HER2-positive advanced gastric cancer and GEJ adenocarcinoma [91]. The gene discussed is ERBB2; the disease is gastric cancer.